about
BAFF, APRIL, TWE-PRIL: Who's who?Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritisBAFF and rheumatic autoimmune disorders: implications for disease management and therapyFeatures associated with epilepsy in the antiphospholipid syndrome.Critical study of staging in multiple myeloma.Role of beta 2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells.Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice.The role of CD5-expressing B cells in health and disease (review).Anti-endothelial cell antibodies in systemic sclerosisCD5 positive B cells in patients with rheumatoid arthritis: phorbol ester mediated enhancement of detection.Drug induced impairment of polymorphonuclear cell bactericidal ability in rheumatoid arthritis.Relation of antivimentin antibodies to anticardiolipin antibodies in systemic lupus erythematosus.Serological abnormalities, including common idiotype PR4, in families with rheumatoid arthritis.Comparison of labial and sublingual salivary gland biopsies in the diagnosis of Sjögren's syndrome.Follow up study of labial salivary gland lesions in primary Sjögren's syndrome.DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus.CD5 expression in human B-cell populations.Autoantibodies to endothelial cell surface ATP synthase, the endogenous receptor for hsp60, might play a pathogenic role in vasculatides.Abnormal distribution of CD45 isoforms expressed by CD4+ and CD8+ T cells in rheumatoid arthritis.Fc-gamma receptor reactivity in nonorgan-specific autoimmune diseases.CD5-positive B cells at the crossroads of B cell malignancy and nonorgan-specific autoimmunity.Anti-endothelial cell autoantibodies and systemic disease.Regulatory B cells play a key role in immune system balance.Recent progress in the understanding of B-cell functions in autoimmunity.Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemiaKetoprofen-induced reduction of polymorphonuclear cell activation in rheumatoid arthritis.Consequences of Fc gamma receptor type III reactivity in non-organ-specific autoimmune diseases.Cytokines Modulate the "Immune-Metabolism" Interactions during Behçet Disease: Effect on Arginine Metabolism.Autoantibodies to heparan sulfate proteoglycans.Antiendothelial cell antibodies in systemic lupus erythematosus.Pathogenic effects of anti-Fc gamma receptor IIIb (CD16) on polymorphonuclear neutrophils in non-organ-specific autoimmune diseases.Anti-endothelial cell antibody, thrombomodulin, and von Willebrand factor in idiopathic inflammatory myopathies.Specificity and idiotope expression of IgM produced by CD5+ and CD5- cord blood B-cell clones.The functional affinity of IgM rheumatoid factor is related to the disease duration in patients with rheumatoid arthritisEx vivo effects of flavonoïds extracted from Artemisia herba alba on cytokines and nitric oxide production in Algerian patients with Adamantiades-Behçet's disease.Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.Neurological Disorders in Primary Sjögren's SyndromeDiagnostic and pathogenic implications of the heterogeneity of antiendothelial cell antibodies.Cutaneous manifestations of primary Sjögren's syndrome are underestimated.The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases.
P50
Q21564037-203139BA-16CF-4722-BA19-994401BD3041Q26991887-9BFD8140-7401-4EF5-8EDE-AA0AA9A1641CQ28292058-BF14F5ED-40B6-4ADE-9F60-DDC423F3A5DBQ33361525-6D659309-F91A-45BE-9AB8-BA247F632E65Q33482200-6D8DCB96-344F-4ABE-A18F-64837CEFC1F9Q33489012-0ADCF890-D13F-456D-93CD-B2B2EE9A6DB1Q33498624-FA705088-E91E-4B29-86F2-E99DF057FE12Q33535364-47DA0F6E-230F-40CE-B02C-16A77333C413Q33538934-1626AD64-0982-4929-BBD7-049FE02F218AQ33557151-2721EC6D-0BB4-4B18-AFB1-2D9B64A46048Q33557178-C8585A6F-B3DD-4AF3-A351-884A0F7FBFD9Q33561066-676D4340-A692-4DE1-8E63-239FC44DAA9AQ33562141-9DAB7DE9-D1B7-49EA-8D9B-030065938B2FQ33562290-6B415C57-452B-4F8D-96D9-62C975436E28Q33564727-FD6C508A-090C-486D-8251-15A01DFA7EE5Q33664826-060EC0D7-A0CE-4A8B-A18B-642A43AF5BE6Q33667776-36CC0C4B-15A1-431C-9C72-634E3618CD5AQ33822283-FDDA1EF9-BEC3-454F-88F6-BFF83ABA35C8Q33917606-760603BE-9F4B-4DAC-B0D8-BCAA57A093EFQ33976561-AA213761-CF3A-4F59-9C88-9EB6CA609AC0Q34018571-403BE38F-69C5-4AAF-A5B9-A7893805EAB9Q34026585-A877D900-C337-4AA4-85B1-EDF58D3E6463Q34033040-287775A2-FCD4-485B-B680-28FF24F98349Q34299834-36EF64C0-1FB9-4513-965A-9D2A1CEB10F2Q34467890-5121040C-DE3B-4A11-A1A4-FA6BDCA738F1Q34691110-2FE6A5DE-EF4C-468A-AD84-A154CF094F0DQ34797822-979DA8FE-C0E7-40FB-8C03-E38C91299FCBQ35066832-2F22EB4D-3EC7-4275-B598-6A0082EEA49CQ35172070-89818BF8-F198-4F30-B7EF-E6ADF4DF5FF7Q35172099-B5880C84-2516-4ECA-9382-9B1A06CD15E3Q35172180-99E45F49-8B8B-4D36-A27D-556B3F0714ACQ35230666-C8FACCCC-0027-4016-ABB8-29B6C47647F8Q35320991-8DE66504-79E5-4DDC-B979-C0AAB1D280C0Q35547092-C974C25C-174C-4E06-B0BA-BFD2FAF7B30DQ35640847-36ABB372-16B8-436F-9954-E1065FEB1A79Q35717890-D8F07909-03E3-4B07-98FA-768AAFAD1500Q35829655-A491BDA3-3F8E-4A52-8FE0-F66963E72CC7Q35862331-461E7864-A6F0-4C34-9C55-69C8C5E4C306Q35918327-8A66383A-ECE8-4D3E-ACE2-E803662D9ACBQ35928662-30C97F13-7BF8-491C-AE3E-442A37C4CB31
P50
description
forsker
@nb
onderzoeker
@nl
researcher
@en
ricercatore
@it
name
Pierre Youinou
@ast
Pierre Youinou
@da
Pierre Youinou
@de
Pierre Youinou
@en
Pierre Youinou
@es
Pierre Youinou
@fr
Pierre Youinou
@nb
Pierre Youinou
@nl
Pierre Youinou
@nn
Pierre Youinou
@sv
type
label
Pierre Youinou
@ast
Pierre Youinou
@da
Pierre Youinou
@de
Pierre Youinou
@en
Pierre Youinou
@es
Pierre Youinou
@fr
Pierre Youinou
@nb
Pierre Youinou
@nl
Pierre Youinou
@nn
Pierre Youinou
@sv
prefLabel
Pierre Youinou
@ast
Pierre Youinou
@da
Pierre Youinou
@de
Pierre Youinou
@en
Pierre Youinou
@es
Pierre Youinou
@fr
Pierre Youinou
@nb
Pierre Youinou
@nl
Pierre Youinou
@nn
Pierre Youinou
@sv
P214
P106
P2038
Pierre_Youinou
P21
P214
P31
P496
0000-0003-2870-749X
P735
P7859
lccn-nb2001025777